Purpose: This randomized, double-blind (DB), non-inferiority phase 3 study was conducted to assess the efficacy and safety of paliperidone palmitate 3-month (PP3M) vs 1-month formulation (PP1M) in European and non-European patients with schizophrenia. Patients and methods: In this randomized, DB, parallel-group study, adult patients (18-70 years) with schizophrenia (per DSM-IV-TR) having Positive and Negative Syndrome Scale (PANSS) total score between 70 and 120; previously stabilized on PP1M were enrolled. The study had 4 phases: screening (3 weeks), open-label (OL) stabilization (17 weeks), DB (48 weeks) and follow-up (4-12 weeks) phase. Patients were treated with fixed-dose PP3M (175-525 mg eq deltoid/gluteal) or PP1M (50-150 mg eq deltoid/gluteal) for 48 weeks in DB phase. Results: In total, 487 European (PP3M, n=242; PP1M, n=245) and 508 non-European patients (PP3M, n=241; PP1M, n=267) entered DB phase (modified intent-to-treat (mITT) [DB] analysis set). Among the 508 non-European patients in mITT set, 67.7% were from Asia (n=344) and 32.3% were from rest of world (ROW, n=164). During the DB phase, similar percentage of Europeans (PP3M: 7%; PP1M: 8%) and non-Europeans (PP3M: 9%; PP1M: 10%) experienced relapse (Kaplan-Meier estimate PP3M-PP1M [95% CI] of percentage of relapse-free patients at the end of DB phase [primary endpoint]: European: 1.0% [−4.3%; 6.2%]; non-European: 1.4% [−4.4%; 7.1%]; Asian: 1.6% [−5.7%; 9.0%]; and ROW: 1.4% [−7.0%, 9.8%], per-protocol analysis set). Incidence of treatment-emergent adverse events (TEAEs) was lower in Europeans (PP3M: 56%, PP1M: 59%) than non-Europeans (PP3M: 80%, PP1M: 73%). The most commonly reported TEAE was weight gain. Conclusion: PP3M showed similar efficacy to PP1M in Europeans and non-Europeans, consistent with non-inferiority of PP3M to PP1M observed in overall population. Rates of AEs were higher in non-Europeans. However, weight gain was greater in non-Europeans, especially the Asian population.
Introduction
Non-adherence and partial adherence to oral antipsychotic regimens is a common challenge in patients with schizophrenia, [1] [2] [3] [4] and is often associated with a poor prognosis for recovery, 5 a negative impact on families and caretakers, and a significant economic burden to the public. 6 Use of long-acting injectable (LAI) antipsychotics has been suggested to support adherence management, 7 and ensure reliable and sustained Paliperidone palmitate 1-month (PP1M) is an LAI formulation approved for the treatment of schizophrenia in several countries, and also for schizoaffective disorder in the USA. 9 A more recently introduced LAI, paliperidone palmitate 3-month (PP3M) formulation, is designed to offer a substantially longer dosing interval, and is approved in the USA, 10 the European Union, 11 and other countries for the maintenance treatment of schizophrenia in patients previously treated with PP1M. Results from two long-term, multicenter phase 3 studies have demonstrated that a larger proportion of patients with schizophrenia, who were stabilized with PP1M for 4 months followed by treatment with PP3M (PP1M × 3.5 doses: 175, 263, 350 or 525 mg eq), did not experience relapse vs placebo. 12 Additionally, PP3M was non-inferior to PP1M with similarly low relapse rates in both groups. 13 Race and ethnic differences as well as differences in healthcare systems may influence treatment response, and safety profiles associated with antipsychotic treatment.
Comparison of efficacy across different geographic regions is important because the response rates sometimes differ. The reasons for such differences are not easy to pinpoint, but may be due to culture, differences in medical care and even pharmacogenetic variations (eg, of the cytochrome P450 family of oxidative enzymes, CYP450) leading to differences in metabolism. Hence, we believe it is important to compare the efficacy across regions. [14] [15] [16] The current study is a subgroup analysis of a long-term, multicenter, phase 3 study that analyzed the non-inferiority of PP3M over PP1M in the treatment of symptoms of schizophrenia. 13 The objective of this subgroup analysis was to assess the comparative efficacy of PP3M vs PP1M in European patients with schizophrenia previously stabilized on PP1M, and to compare their efficacy and safety outcomes with non-European populations.
Patients and methods study population
This subgroup analysis was based on data from a phase 3, double-blind (DB), parallel-group, non-inferiority study. (EudraCT Number: 2011-004889-15) conducted at 199 sites across 26 countries from April 2012 to March 2015 (16 countries in Europe). The primary study is published elsewhere. 13 In brief, this randomized study enrolled adult (18-70 years old) patients of either sex, with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, fourth-Edition [DSM-IV-TR]), having a screening and baseline Positive and Negative Syndrome Scale (PANSS) total score between 70 and 120, and with deterioration of schizophrenia symptoms. Patients who stopped other antipsychotics because they preferred injectables or as a result of insufficient efficacy or safety or tolerability concerns with the existing therapy were included in the present study.
The key exclusion criteria were: patients with active DSM-IV diagnoses besides schizophrenia, significant suicidal behavior risk substance dependence 6 months before screening, tardive dyskinesia, neuroleptic malignant syndrome, significant medical or neurological illness, mental retardation, morbid obesity (BMI 40 kg/m 2 ), prolonged QT interval risk factors, torsades de pointes, or sudden death. Other exclusion criteria were: no response, or history of intolerability, or hypersensitivity to risperidone or paliperidone.
The study protocol and amendments were reviewed and approved by each site's Independent Ethics Committee or Institutional Review Board (Supplementary material). The study was conducted in compliance with the Declaration of Helsinki and applicable regulatory requirements. All patients provided written informed consent prior to study enrollment.
study design
The study was divided into 4 phases: up to 3 weeks screening, 17 weeks open-label (OL) stabilization (flexible doses), 48 weeks DB (fixed doses) and 4-12 weeks follow-up. Oral tolerability testing was performed during screening (paliperidone extended release 6 mg/day for 4-6 consecutive days) in patients who were not previously exposed to oral or injectable risperidone or paliperidone. After completing the screening phase and meeting all eligibility criteria, patients entered the OL stabilization phase where they received PP1M as follows: 150 mg eq (deltoid) on day 1; 100 mg eq (deltoid) on day 8; flexibly dosed 50, 75, 100, or 150 mg eq (deltoid or gluteal) at weeks 5 and 9; and same PP1M dose as week 9 maintained at week 13. Clinically stable patients (defined as patients with 70 PANSS total score with 4 PANSS item [P1, P2, P3, P6, P7, G8, G14] scores and 1 reduction at weeks 14 and 17 from OL baseline in CGI-S score) then began the DB phase of 48 weeks. In the DB phase, patients were randomized (1:1) to fixed doses of 175, 263, 350, or 525 mg eq PP3M at weeks 17, 29, 41 and 53; or 50, 75, 100, or 150 mg eq PP1M every month. 13 Blinding was maintained in the PP3M group with monthly matched placebo injections (20% Intralipid ® ) as a substitute for active medication. 
Efficacy
The percentage of patients who remained relapse-free (based on the Kaplan-Meier cumulative estimate of survival) by the end of DB phase (48 weeks) was the endpoint for primary efficacy. Relapse was defined as one or more of the following: 1) hospitalization for symptoms of schizophrenia (involuntary or voluntary admission); 2) for patients scoring 40 at randomization, an increase of 25% in PANSS total score from randomization for two consecutive assessments (3-7 days apart) or an increase in 10 points for patients who scored 40 at randomization; 3) increase in distinct PANSS item scores (P1, P2, P3, P6, P7, or G8) for two consecutive assessments (3-7 days apart; increase defined as PANSS item scores 5 after randomization for 2 consecutive assessments separated by 3-7 days if the maximum score for the above PANSS items was 3 at randomization, or 6 after randomization if the maximum score for the above PANSS items was 4 at randomization); 4) deliberate self-injury or violent behavior that was clinically significant; and 5) suicidal or homicidal ideation and aggressive behavior. Based on PANSS ratings, the occurrence of relapse was ascertained when the increased symptoms were first presented and a second assessment (within 3-7 days post first assessment) further confirmed it.
The secondary efficacy endpoints included changes from baseline (DB phase) to DB endpoint in PANSS total score, Clinical Global Impressions of Severity (CGI-S) scale, Personal and Social Performance (PSP) scale, proportion of patients who achieved symptomatic remission during the last 6 months before the end of DB phase (defined as meeting the Andreasen et al 17 remission criteria during the 6 months prior to end of DB phase, with no excursion allowed), and proportion of patients who achieved both symptomatic and functional remission. Criterion for symptomatic remission was defined as having a simultaneous score of mild or less on all selected PANSS items (P1, P2, P3, N1, N4, N6, G5, and G9). Functional remission criterion was defined as having PSP score 70. 
statistical analysis sample size determination
The target overall sample size of the global study was 1,388 patients. Assuming a relapse-free rate of 70% for PP1M, a true difference of 4% in relapse-free survival favoring PP1M vs PP3M, and a 1-sided significance level of 2.5%, 380 patients per treatment group were required to demonstrate with 90% power that PP3M was similar to PP1M by a non-inferiority margin of 15% in relapse-free survival rates. Although the subgroup analysis part of the study was not powered, the global study was designed to have a sufficiently large European population to show consistency of results between the global population and the European population.
statistical analyses
The Kaplan-Meier method was used to derive the 48-week cumulative estimate of relapse-free survival. Greenwood's formula was used to compute the standard error (SE) estimates. Treatment comparisons during the DB phase between PP3M and PP1M for the changes from baseline for PANSS total score, PSP, and CGI-S were performed by an analysis of covariance (ANCOVA) model where treatment and country were factors and baseline (DB phase) value was a covariate. Proportion of patients who achieved symptomatic remission 17 was evaluated using the Cochran-MantelHaenszel test controlling for country. The point estimate and 95% CI for the relative risk of remission were presented. Safety results were analyzed descriptively.
The intent-to-treat (ITT) OL analysis set was used for all efficacy and safety analyses for the OL phase and included all patients who had received at least 1 dose of study drug during the OL phase. The primary efficacy analysis was performed by using the per-protocol (PP) analysis set, which included all randomized patients who received at least 1 dose of study drug during the DB phase and did not have major protocol violations (eg, violations of intended study population treatment assignment errors or excluded medication use). For all secondary efficacy analyses for the DB phase, the modified ITT-DB analysis set (mITT-DB, defined as all patients who received at least 1 dose of study drug during the DB phase, with no errors in the delivery of active treatment due to manufacturing of the investigational product) was used. DB phase safety analyses were performed using the safety analysis set (defined as all patients who received at 
Results

Patient demographics
Overall, 647 European patients were enrolled in the study and were treated in the OL phase (ITT [OL] analysis set) ( Table 1) , and 498 (77% of those enrolled in the OL phase) European patients (PP3M: n=253; PP1M: n=245) were randomized to the DB phase (Table 1 ). In the OL phase, the most common reasons for discontinuation were lack of efficacy (8%, n=54) and withdrawal of consent (6%, n=42; Figure 1 ). The PP-analysis set included 467/498 randomized patients, (PP3M: n=229; PP1M: n=238), while the mITT (DB) analysis set included 487/498 patients (PP3M: n=242; PP1M: n=245). In total, 414 (85%) patients completed the DB phase (inclusive of relapsed patients, mITT [DB] analysis set; in both the treatment arms, the proportion was similar for completion (PP3M, 86% and PP1M, 84%) and for completion without a relapse (PP3M: n=189, 78%; PP1M: n=187, 76%). In the DB phase, most patients discontinued as they withdrew consent ( Figure 1 ).
For non-European regions, 782 patients were enrolled and received treatment in the OL phase (ITT [OL] analysis set; patients from Asia: 510 and patients from ROW: 272); of these, 518 patients (66% of patients enrolled in OL) were randomized in the DB phase (PP3M: n=251; PP1M: n=267) ( Table 1 ). In total 481/518 randomized patients were included in the PP-analysis set (Asia: n=335; ROW: n=146), while 508 patients were included in the mITT (DB) analysis set (PP3M: n=241; PP1M: n=267; Asia: 344 patients [PP3M: n=170; PP1M: n=174]; ROW: n=164 [PP3M: n=71; PP1M: n=93]; mITT [DB] analysis set).
In total, 410 (81%) non-European patients completed the DB phase (including patients with relapse, mITT [DB] (6) 12 (5) 16 (7) czech republic 69 (11) 31 (13) 29 (12) France
hungary 51 (8) 21 (9) 19 (8) Poland 56 (9) 17 (7) 20 (8) Portugal 30 (5) 11 (5) 10 (4) romania 20 (3) 7 (3) 6 (2) russian Federation 177 (27) 70 (29) 75 (31) slovakia 23 (4) 12 (5) 10 (4) spain 42 (6) 11 (5) 14 (6) sweden 2 (1) 0 0 Ukraine 72 (11) 29 (12) 29 (12) (Continued) (21) 32 (13) 48 (18) Notes: iTT-Ol, all patients who had received at least 1 dose of study drug during the OL phase; mITT-DB, defined as all patients who received at least 1 dose of study drug during the DB phase, and had no errors in the delivery of active treatment due to the manufacturing of the investigational product. Baseline (OL) characteristics were similar across both European and non-European patients except that most patients in the European subgroup were white (97%) while a majority of patients in the non-European subgroup were Asians (65%). Current nicotine usage was higher in the European (53%) vs non-European subgroup (35%) ( Table 2) . Among the 508 non-European patients in mITT (DB) set, 67.7% were from Asia (n=344) and 32.3% were from rest of world (ROW, n=164) ( Table 2 ).
Prior and concomitant medications
Before entry into the study, similar percentage of patients in the European (92%) and non-European subgroups (89%) received 1 psychotropic medications (Table 2) . During the DB phase, a higher percentage of patients in the nonEuropean subgroup received benzodiazepines (safety analysis set, n=145, 28%; lorazepam: n=102, 20%) than European subgroup (safety analysis set, n=97, 19%; lorazepam: n=34, 7%). However, within the subgroups, similar percentage of patients treated with PP3M and PP1M received benzodiazepines during the DB phase (European subgroup, PP3M: n=46, 18%; PP1M: n=51, 21%; non-European subgroup, PP3M: n=74, 29%; PP1M: n=71, 27%) with lorazepam overall being the most common (10% patients) benzodiazepine 
Notes:
The follow-up visit was 4 weeks after the end-of-study visit for those patients who completed the DB phase without a relapse and 12 weeks for those who withdrew early or had a relapse during the DB phase. In OL phase, patients received PP1M on day 1 (150 mg eq deltoid), day 8 (100 mg eq deltoid), wherein flexible dosing was administered at weeks 5 and 9. PP1M: 50, 75, 100 or 150 mg eq dose; PP3M: 175, 263, 350, 525 mg eq dose (3.5 × PP1M dose 
Sex, n (%) Men
(55)
126 (52) 134 (55) 242 (47) 79 (46) 86 (49) 181 (67) 42 (59) 61 (66) 423 (54) 121 (50) 147 ( 43 (61) 57 (61) 152 (19) 43 (18) 57 (21) Black or african american
24 (34) 34 (37) 109 (14) 24 (10) 34 ( (2) 1 (1) 1 (1) 5 (1) 1 ( 122 (50) 128 (52) 114 (22) 35 (21) 36 (21) 157 (58) 31 (44) 49 (53) 271 (35) 66 (27) 85 (32) Former 39 (6) 14 (6) 18 (7) 43 (8) 12 (7) 20 (11) 22 (8) 7 (10) 6 (6) 65 (8) 19 (8) 26 (10) Never 263 (41) 106 (44) 99 (40) 353 (69) 123 (72) 118 (68) 93 (34) 33 (46) 38 (41) 446 (57) 156 (65) 156 (58)
Most common (10% patients) prior psychotropic medications, n (%) Atypical antipsychotics
(74)
177 (73) 181 (74) 422 (83) 139 (82) 141 (81) 181 (67) 48 (68) 60 (65) 603 (77) 187 (78) 201 (75) risperidone 192 (30) 69 (29) 71 (29) 226 (44) 73 (43) 75 (43) 74 (27) 20 (28) 24 (26) 300 (38) 93 (37) 99 (37) Paliperidone 141 (22) 52 (21) 56 (23) 132 (26) 42 (25) 44 (25) 31 (11) 9 (13) 12 (13) 163 (21) 51 (20) 56 (21) Olanzapine 118 (18) 40 (17) 45 (18) 70 (14) 19 (11) 24 (14) 39 (14) 11 (15) 16 (17) 109 (14) 30 (12) 40 (15) aripiprazole 53 (8) 15 (6) 17 (7) 63 (12) 28 (16) 15 (9) 25 (9) 5 (7) 11 (12) 88 (11) 33 (13) 26 (10) Quetiapine 75 (12) 30 (12) 29 (12) 54 (11) 22 (13) 17 (10) 27 (10) 6 (8) 6 (6) 81 (10) 28 (11) 23 (9) Benzodiazepines 194 (30) 54 (22) 69 (28) 228 (45) 67 (39) 65 (37) 100 (37) 23 (32) 34 (37) 328 (42) 90 (36) 99 (37) Diazepam 68 (11) 17 (7) 23 (9) 16 (3) 4 (2) 4 (2) 8 (3) 3 (4) 3 (3) 24 (3) 7 (3) 7 (3) lorazepam 55 (9) 16 (7) 19 (8) 116 (23) 32 (19) 38 (22) 61 (22) 12 (17) 19 (20) 177 (23) 44 (18) 57 (21) clonazepam 54 (8) 18 (7) 22 (9) 40 (8) 6 (4) 13 (7) 30 (11) 10 (14) 10 (11) 70 (9) 16 (6) 23 (9) Typical antipsychotics 177 (27) 57 (24) 64 (26) 98 (19) 23 (14) 33 (19) 50 (18) 17 (24) 17 (18) 148 (19) 40 (16) 50 ( 31 (13) 29 (12) 45 (9) 13 (8) 14 (8) 31 (11) 9 (13) 11 (12) 76 (10) 22 (9) 25 (9)
Anti-EPS
112 (17) 28 (12) 48 (20) 153 (30) 54 (32) 41 (24) 47 (17) 12 (17) 17 (18) 200 (26) 66 (26) 58 (22) Biperiden 64 (10) 20 (8) 24 (10) 47 (9) 17 (10) 11 (6) 21 (8) 6 (8) 8 (9) 68 (9) 23 (9) 19 (7) Trihexyphenidyl 44 (7) 8 (3) 19 (8) 95 (19) 34 (20) 29 (17) 1 (1) 0 0 96 (12) 34 (14) 29 (11) Non-benzodiazepines hypnotics and anxiolytics 49 (8) 16 (7) 18 (7) 135 (26) 38 (22) 46 (26) 62 (23) 16 (23) 15 (16) 197 (25) 54 (22) 61 (23) Zolpidem 40 (6) 13 (5) 13 (5) 29 (6) 10 (6) 9 (5) 52 (19) 13 (18) 12 (13) 96 (12) 23 (9) 21 (8)
2 (1) 4 (2) 92 (18) 21 (12) 36 (21) 4 (1) 2 (3) 1 (1) 81 (10) 23 (9) 37 (14) Baseline (DB) PANSS total score, mean (SD) (European subgroup, PP3M: n=15, 6%; PP1M: n=19, 8%; non-European subgroup, PP3M: n=51, 20%; PP1M: n=51, 19%).
extent of exposure
Similar exposure was observed in all three subgroups (European, Asian and ROW) between patients from both treatment groups (Table 3) . Patients in European, Asian and ROW subgroup received similar mean (SD) PP3M dose and PP1M dose.
Efficacy
In the European subgroup, a similar proportion of patients in both treatment groups (PP-analysis set, PP3M: 7%, n=17; PP1M: 8%, n=20) relapsed during the DB phase. Results were consistent in the non-European subgroup (PP-analysis set, PP3M: 9%, n=20; PP1M: 10%, n=25; Asia: n=37, 11% . Due to the low number of relapses, the median time-to-relapse was not estimable in both European and non-European subgroups for patients in both treatment groups ( Figure 2 ). The secondary efficacy endpoints (PANSS total score, CGI-S and PSP scores) also showed similar improvements in both treatment groups from DB baseline to DB endpoint in European and non-European patients (Table 4 and Figure 3) . In both treatment groups of European patients, a similar percentage (52% in each group) showed symptomatic remission with 0.98 (95% CI: 0.83, 1.15) relative risk of remission for PP3M vs PP1M. Similar percentage of European patients in both PP3M and PP1M achieved symptomatic remission as well as both the symptomatic and functional remission at different timepoints during the DB phase (Figure 4 ). a Based on analysis of covariance (aNcOVa) model with treatment and country as factors, and baseline (DB) value as a covariate; b Diff (PP3M-PP1M) is for change from baseline; mITT-DB, defined as all patients who received at least 1 dose of study drug during the DB phase, and had no errors in the delivery of active treatment due to the manufacturing of the investigational product. Abbreviations: CGI-S, Clinical Global Impression-Severity; DB, double-blind; mITT-DB, modified intent-to-treat; PANSS, Positive and Negative Syndrome Scale; PP1M, paliperidone palmitate 1-month formulation; PP3M, paliperidone palmitate 3-month formulation; PsP, Personal and social Performance. 
PP1M (N=267)
Teae, n (%)
308 (48) 142 (56) 145 (59) 364 (71) 138 (81) 132 (76) 174 (64) 62 (77) 63 (68) 538 (69) 200 (80) 195 (73) at least 1 possibly related Teae, n (%)
189 (29) 78 (31) 87 (36) 238 (47) 92 (54) 84 (48) 135 (50) 40 (49) 38 (41) 373 (48) 132 (53) 122 (46) Teae leading to drug withdrawal a , n (%)
24 (4) 7 (3) 5 (2) 25 (5) 6 (4) 4 (2) 11 (4) 2 (3) 4 (4) 36 (5) 8 (3) 8 (3) sae with fatal outcome (death), n (%) 0 0 2 (1)
1 or more serious TEAE, n (%)
40 (6) 14 (6) 14 (6) 43 (8) 9 (5) 16 (9) 18 (7) 3 (4) 7 (8) 61 (8) 12 (5) 23 (9) Most common (1% incidence) serious TEAEs, n (%) schizophrenia 15 (2) 9 (4) 6 (2) 15 (3) 3 (2) 4 (2) 1 (1) 0 1 (1) 16 ( 28 (11) 37 (15) 29 (6) 53 (31) 54 (31) 30 (11) 24 (30) 18 (19) 59 (8) 77 (31) 72 (27) Nasopharyngitis 17 (3) 20 (8) 11 (5) 44 (9) 14 (8) 19 (11) 5 (2) 2 (3) 3 (3) 49 (6) 16 (6) 22 (8) schizophrenia 20 (3) 13 (5) 7 (3) 17 (3) 4 (2) 4 (2) 4 (2) 1 (1) 3 (3) 21 (3) 5 (2) 7 (3) anxiety 28 (4) 11 (4) 12 (5) 46 (9) 12 (7) 8 (5) 9 (3) 4 (5) 4 (4) 55 (7) 16 (6) 12 (5) headache 19 (3) 10 (4) 16 (7) 13 (3) 3 (2) 3 (2) 14 (5) 5 (6) 7 (8) 27 (4) 8 (3) 10 (4) injection site pain 69 (11) 8 (3) 13 (5) 41 (8) 3 (2) 0 17 (6) 1 (1) 1 (1) 58 (7) 4 (2) 1 (1) insomnia 27 (4) 7 (3) 12 (5) 58 (11) 6 (4) 6 (3) 11 (4) 3 (4) 6 (7) 69 (9) 9 (4) 12 (5) akathisia 19 (3) 5 (2) 2 (1) 50 (10) 10 (6) 8 (5) 13 (5) 5 (6) 4 (4) 63 (8) 15 (6) 12 (5) Treatment-emergent EPS events, total, n (%)
42 (6) 14 (6) 10 (4) 104 (20) 19 (11) 20 (12) 34 (13) 9 (11) 8 (9) 138 (18) 28 (11) 28 (11) Most common (1% incidence) EPS-related TEAEs, n (%) akathisia 19 (3) 5 (2) 2 (1) 50 (10) 10 (6) 8 (5) 13 (5) 5 (6) 4 (4) 63 (8) 15 (6) 12 ( (1) 3 (1) 1 (1) 1 (1) 15 (2) 1 (1)
(1)
Tremor 8 (1) 5 (2) 1 (1)
11 (2) 2 (1) 1 (1) 3 (1) 2 (2) 1 (1) 14 (2) 4 (2) 2 (1) Musculoskeletal stiffness 1 (1)
2 (1) 3 (1) 3 (1) 1 (1) 4 (2) 6 (2) 0 2 (2) 9 (1) 1 ( 5 (2) 8 (3) 6 (1) 8 (5) 10 (6) 6 (2) 0 7 (8) 12 (2) 8 (3) 17 (6) Blood glucose increased
3 (1) 4 (2) 3 (2) 2 (1) 0 3 (3) 5 (1) 4 (2) 6 (2) hyperglycemia 0 2 (1) 4 (2) 1 (1)
2 (1) 3 (2) 2 ( Injection site-related TEAEs, total, n (%) 86 (13) 17 (7) 18 (7) 69 (14) 18 (11) 7 (4) 31 (11) 5 (6) 5 (5) 100 (13) 23 (9) 12 (5) Most common (1% incidence) injection site-related TEAEs, n (%) injection site induration 11 (2) 4 (2) 2 (1) 25 (5) 9 (5) 4 (2) 4 (1) 1 (1) 0 29 (4) 10 (4) 4 (2) injection site pain 69 (11) 8 (3) 13 (5) 41 (8) 3 (2) 0 17 (6) 1 (1) 1 (1) 58 (7) 4 (2) 1 (1)
injection site swelling 4 (1) 4 (2) 1 (1)
8 (2) 3 (2) 1 (1) 2 (1) 0 0 10 (1) 3 (1) 1 (1)
injection site erythema 8 (1) 2 (1) 1 (1)
6 (1) 2 (1) 1 (1) 0 0 1 (1) 6 (1) 2 (1) 2 (1) Pain in extremity
1 (1) 10 (4) 2 (1) 2 (2) 10 (1) 3 (1) 3 (1) Notes:
a an adverse event that started in the Ol phase and resulted in study drug being discontinued in the DB phase is counted as treatment-emergent in the Ol phase; all percentages are rounded off to nearest whole integer; iTT [Ol] analysis set, all patients who had received at least 1 dose of study drug during the OL phase; safety analysis set defined as all patients who received at least 1 dose of study drug during the DB phase. Abbreviations: DB, double-blind; iTT, intend-to-treat; Ol, open-label; PP1M, paliperidone palmitate 1-month formulation; PP3M, paliperidone palmitate 3-month formulation; sae, serious adverse event; Teae, treatment-emergent adverse event. Table 5 ). Incidence of EPSrelated TEAEs was similar between PP3M and PP1M treated patients of European and non-European subgroups; however, the incidence was slightly more in the non-European subgroup than the European subgroup ( Table 5) .
The mean (SD) weight change from OL baseline to DB endpoint was similar between PP3M and PP1M treated patients of both European as well as non-European subgroups, though weight gain was overall less in the European population (Europe, PP3M: 1.3 [6.52] (Table 6 ). Diabetes mellitus and hyperglycemiarelated TEAEs were low and similar between PP3M and PP1M-treated patients in the European, Asian and ROW subgroups (Table 5) . Incidence of injection site-related TEAEs was similar between PP3M and PP1M-treated patients of the European, Asian and ROW subgroups during the DB phase ( Table 5 ). The local injection site tolerability was good in European, Asian and ROW subgroups.
Discussion
The results of the current subgroup analysis demonstrated the non-inferiority of PP3M to PP1M; primary efficacy results (ie, relapse-free rates at end of 48-week DB phase) in European and non-European (which had a significant proportion of Asian population [65%]) subgroups are similar and consistent with that observed in the global population. 13 Most patients in both subgroups (70%) on both treatments completed the 48-week DB phase without a relapse. These findings are consistent with the results of the global study. 13 The secondary efficacy endpoint results also suggested that PP3M showed similar efficacy to PP1M in the maintenance treatment of European patients with schizophrenia. patients compared with non-European patients; this may be due to higher baseline BMI in European patients compared with the ROW which were majority Asian. [26] [27] [28] Evidence also suggests that baseline BMI differs between Asians and Europeans. 29 A subgroup analysis of the same study comparing the Asian and global populations demonstrated that incidence of weight gain was greater in the Asian subgroup (31% in both groups) compared with the global population (21% in both groups). 19 The extent of weight gain in the Asian subgroup (2 kg) was comparable with the global population (~1.5 kg) 19 and was consistent with earlier studies. 22, 23, 25 Previous studies also reported similar weight gain in Asian patients treated with PP1M. 30, 31 No new safety signals emerged. This study, as a post hoc study, was not powered to show statistical significance for a subgroup analysis. However, the primary study was a fully powered non-inferiority study and enrolled a sufficient number of patients to derive meaningful conclusions from this subgroup analysis. Unlike real life practice, PP3M-treated patients in both European and non-European subgroups had only 2 opportunities for dose adjustments. Further, all patients received monthly injections to maintain the blind. The high completion rates, low relapse rates and low discontinuations due to TEAEs can be Table 6 Body weight, BMi, and waist circumference -change from baseline (Ol) to endpoint (DB) -europe vs non-europe (asia, rest of the world and total non-europe) (safety analysis set) Symptomatic remission was achieved in the majority of European and non-European patients in both treatment groups throughout the last 6 months of DB treatment. These results are in agreement with the findings of similar relapse-prevention studies assessing the efficacy of PP1M in maintaining symptomatic control in patients with schizophrenia, [20] [21] [22] [23] [24] [25] and the long-term maintenance study using PP3M. 12 Comparable safety and tolerability profiles were noted for PP3M and PP1M during the DB phase in the European patients. Incidence of TEAEs was lower in the European patients compared with the non-European patients. It should be noted that the majority of patients in the non-European subgroup were Asians and Asian patients have been shown to be somewhat more susceptible to adverse events. 19 Low discontinuations due to TEAEs were comparable for PP1M and PP3M treatments in European and non-European subgroups. Serious TEAEs were similar between both treatment groups in European and non-European patients and were mostly psychiatric-related. Weight gain and nasopharyngitis were the most common TEAEs observed in both treatment groups. A higher incidence of akathisia, and increased glucose levels were observed in the non-European population compared with the European population. Weight gain was less in European 
601
savitz et al attributed to the fact that patients who entered the DB phase were already able to tolerate and respond to PP1M. Some varied responses observed in the study may be attributed to the occurrence of different ethnicities as well as differences in healthcare delivery within the European populations. PP3M could offer advantages by enhancing the number of available treatment options and potentially offering improved outcomes for European patients with schizophrenia.
Conclusion
The efficacy findings of this subgroup analysis (between European and non-European patients) corroborate those of the primary study in PP3M-and PP1M-treatment groups. A greater percentage of non-Europeans, especially Asian population, had weight gain compared to Europeans. No new safety signals were noted during the course of this study. Therefore, PP3M could be considered as a useful treatment option to prevent relapse in schizophrenia in European patients.
Data sharing statement
Will individual participant data be available (including data dictionaries)?
The data sharing policy of Janssen Pharmaceutical companies of Johnson & Johnson is available at https://www. janssen.com/clinical-trials/transparency. as noted on this site, requests for access to the study data can be submitted through Yale Open Data access (YODa) Project site at http:// yoda.yale.edu.
What data in particular will be shared What other documents will be available?
With whom?
By what mechanism will data be made available? how long the data is available?
